RARE
Ultragenyx Pharmaceutical Inc. · Healthcare
Insiders sold $3.7M of Ultragenyx Pharmaceutical Inc. in the last 12 months and bought none
RARE over the last year
RARE after insider buys
3 months after each buy, from the first price a copier could get.
No buys have 3 months of prices yet. A record shows here at 3.
Congress
Members reported 5 trades in RARE since 2025.
Every filing
169 insider filings since 2016, newest first
Theodore Alan Huizenga · SVP and Chief Accounting Officer
Mardi Dier · CFO and EVP
Mardi Dier · CFO and EVP
Thomas Richard Kassberg · CBO, EVP
Karah Herdman Parschauer · EVP and General Counsel
Erik Harris · EVP and Chief Commercial Officer
John Richard Pinion · Insider
Theodore Alan Huizenga · SVP and Chief Accounting Officer
Dennis Karl Huang · Insider
Karah Herdman Parschauer · EVP and General Counsel
Mardi Dier · CFO and EVP
Thomas Richard Kassberg · CBO, EVP
Camille L Bedrosian · EVP and Chief Medical Officer
Camille L Bedrosian · EVP and Chief Medical Officer
Dennis Karl Huang · EVP and Chief Tech Ops Officer
Karah Herdman Parschauer · EVP and General Counsel
John Richard Pinion · Insider
Camille L Bedrosian · EVP and Chief Medical Officer
Mardi Dier · CFO and EVP
Karah Herdman Parschauer · EVP and General Counsel
Camille L Bedrosian · EVP and Chief Medical Officer
Erik Harris · EVP and Chief Commercial Officer
Erik Harris · EVP and Chief Commercial Officer
Karah Herdman Parschauer · EVP and General Counsel
Dennis Karl Huang · EVP and Chief Tech Ops Officer
Karah Herdman Parschauer · EVP and General Counsel
John Richard Pinion · Insider
Erik Harris · EVP and Chief Commercial Officer
Thomas Richard Kassberg · CBO, EVP
Camille L Bedrosian · EVP and Chief Medical Officer
Emil D Kakkis · President and CEO
Erik Harris · EVP and Chief Commercial Officer
Camille L Bedrosian · EVP and Chief Medical Officer
Theodore Alan Huizenga · SVP, Controller, PAO
John Richard Pinion · Insider
Karah Herdman Parschauer · EVP and General Counsel
Theodore Alan Huizenga · SVP, Controller, PAO
Erik Harris · EVP and Chief Commercial Officer
Dennis Karl Huang · EVP and Chief Tech Ops Officer
Emil D Kakkis · President and CEO
Thomas Richard Kassberg · CBO, EVP
Camille L Bedrosian · EVP and Chief Medical Officer
William Aliski · Director
Erik Harris · EVP and Chief Commercial Officer
Camille L Bedrosian · EVP and Chief Medical Officer
Camille L Bedrosian · EVP and Chief Medical Officer
Theodore Alan Huizenga · SVP, Controller, PAO
Emil D Kakkis · President and CEO
Emil D Kakkis · President and CEO
Karah Herdman Parschauer · EVP and General Counsel
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.